Disease-Associated [Microglia](/cell-types/microglia-neuroinflammation) (DAM)

Disease-Associated Microglia (DAM)

Overview

Disease Associated Microglia (Dam) plays an important role in the study of neurodegenerative . This page provides comprehensive information about this topic, including its , significance in disease processes, and therapeutic implications. @neuromodulatory]

Introduction

Disease-Associated Microglia (DAM)

Overview

Disease Associated Microglia (Dam) plays an important role in the study of neurodegenerative . This page provides comprehensive information about this topic, including its , significance in disease processes, and therapeutic implications. @neuromodulatory]

Introduction

Disease Associated microglia et al. (2017) in the 5xFAD mouse model of alzheimers, DAM are defined by downregulation of homeostatic microglial genes and upregulation of genes involved in lipid metabolism, phagocytosis, and innate immune activation. Remarkably, the DAM transcriptional signature is conserved across multiple neurodegenerative , including als, parkinsons, and age-related neurodegeneration, suggesting a universal microglial response to neuronal injury. @receptors]

DAM have attracted intense research interest because they express many known genetic risk factors for Alzheimer's disease — including [TREM2](/proteins/trem2) and [APOE](/proteins/apoe). [@mitochondrial]

Discovery and Characterization

Single-Cell Transcriptomic Identification

The DAM phenotype was discovered through unbiased single-cell RNA sequencing of brain microglia and identified a population of microglia expressing:

• Itgax (CD11c — integrin involved in phagocytosis)
• Clec7a (Dectin-1 — pattern recognition receptor)
• Spp1 (osteopontin — extracellular matrix protein)
• Axl and Tyro3 (TAM receptor kinases — efferocytosis)
• Cd9 (tetraspanin involved in cell adhesion and migration)
• Gpnmb (glycoprotein nonmetastatic melanoma protein B)
• Clec7a (Dectin-1 — pattern recognition receptor)
• Spp1 (osteopontin — extracellular matrix protein)
• Axl and Tyro3 (TAM receptor kinases — efferocytosis)
• Cd9 (tetraspanin involved in cell adhesion and migration)
• Gpnmb (glycoprotein nonmetastatic melanoma protein B)

Two-Stage Activation Model

DAM activation occurs through a stepwise process: [@persistent]

Stage 1 (TREM2-independent):

• Triggered independently of TREM2 signaling

• Full activation of the DAM program requires TREM2 signaling
• Enhanced phagocytic capacity and migration toward pathology
• TREM2 is a cell-surface receptor on microglia that signals through DAP12 (TYROBP) to activate PI3K/Akt and Syk-dependent pathways (Ulland and Colonna, 2018)

• Phospholipids (phosphatidylserine, phosphatidylcholine) on apoptotic [neurons](/entities/neurons)
• [amyloid-beta](/proteins/amyloid-beta) oligomers and fibrils
• [APOE](/proteins/apoe). Krasemann et al. (2017) identified the TREM2-APOE pathway as a key regulatory axis driving the transcriptional phenotype of dysfunctional microglia across neurodegenerative diseases
• TREM2 activation induces apoe.

DAM in Specific Diseases

Alzheimer's Disease

DAM are most extensively characterized in alzheimers models and human tissue: [@li2019]

• Plaque association: DAM preferentially cluster around amyloid-beta plaques, forming a barrier that compacts plaques and limits their toxic halo (Yuan et al., 2016)
• Amyloid clearance: TREM2-dependent phagocytosis of amyloid fibrils and damaged myelin
• Plaque seeding: Elevating TREM2 reduces amyloid seeding and suppresses DAM in early disease stages (Dhandapani et al., 2022)
• [tau](/proteins/tau)-protein interaction: DAM response may promote tau propagation] through exosome release and inflammatory signaling
• Human validation: scRNA-seq of human AD brains confirms the presence of DAM-like populations, though with some species-specific differences (Zhou et al., 2020)

Amyotrophic Lateral Sclerosis (ALS)

DAM are found in als spinal cord, particularly near degenerating motor neurons: [^10]

• sod1-protein mutant mice show progressive DAM accumulation
• The DAM signature in ALS overlaps substantially with AD, suggesting a conserved response
• TREM2 deficiency accelerates disease progression in SOD1 mice
• DAM may support motor neuron survival in early disease but become dysfunctional with chronic activation

Parkinson's Disease

In parkinsons and related synucleinopathies: [^11]

• DAM-like microglia are found near [alpha-synuclein](/proteins/alpha-synuclein) pathology
• [lrrk2](/entities/lrrk2) mutations affect microglial inflammatory responses and DAM activation
• [gba](/entities/gba) mutations alter lipid metabolism in microglia, potentially affecting DAM function
• substantia-nigra microglia show unique vulnerability profiles

Multiple Sclerosis

DAM contribute to both pathology and repair in multiple-sclerosis: [^12]

• Active lesions show abundant DAM with phagocytic activity directed at myelin debris
• Efficient myelin debris clearance by DAM is required for remyelination
• Chronic active lesion rims ("smoldering plaques") contain iron-laden, dysfunctional DAM
• The EAE model shows TREM2-apoe

LDAM are a recently described subset characterized by (Li et al., 2025): [@sala2019]

• Accumulation of intracellular lipid droplets
• Impaired phagocytic capacity
• Elevated oxidative-stress and oxidative-stress production
• Dysregulated lipid metabolism
• Increased with aging and in neurodegenerative disease
• May represent a late-stage DAM phenotype or a distinct microglial state
• Emerging as therapeutic targets for age-related neurodegeneration

Dark Microglia

Identified by electron microscopy, dark microglia are ultrastructurally distinct cells found near amyloid plaques. They show condensed cytoplasm, nuclear chromatin, and extensive contacts with synapses. They may represent a morphological correlate of the DAM transcriptional state. [@goate2025]

Interferon-Responsive Microglia (IRM)

A microglial subtype characterized by upregulation of type I interferon-stimulated genes. IRM are found in aging and AD brains and may represent a parallel but distinct activation pathway from DAM, driven by the sting-pathway pathway] and |[NF-κB](/entities/nf-kb) signaling. [@mullard2025]

Dual Roles: Neuroprotection vs. Neurotoxicity

Evidence for Neuroprotective Functions

• Amyloid compaction: DAM form a protective barrier around amyloid-beta plaques, limiting toxic oligomer release
• Phagocytic clearance: Enhanced phagocytosis of cellular debris, damaged myelin, and protein aggregates
• Neurotrophic support: DAM express growth factors and survival signals
• TREM2 loss-of-function worsens disease: TREM2 knockout exacerbates neurodegeneration in most models, suggesting DAM serve an essential protective role
• Synaptic protection: DAM may clear complement-system-tagged dysfunctional synapses while preserving healthy connections

Evidence for Neurotoxic Functions

• Chronic inflammation: Sustained DAM activation drives chronic neuroinflammation through cytokine release (TNF-α, IL-1β, IL-6)
• Excessive synaptic pruning: DAM-mediated complement-dependent phagocytosis of synapses may be excessive, contributing to synaptic-dysfunction
• Tau propagation: DAM may facilitate tau propagation] through phagocytosis and release of tau-containing [exosomes](/entities/exosomes)
• Oxidative damage: Activated DAM produce oxidative-stress that damage surrounding neurons
• Loss of homeostatic functions: Downregulation of homeostatic genes means loss of normal microglial surveillance and neuron-support functions

Context-Dependent Function

The emerging consensus is that DAM function is context-dependent (Yin et al., 2025): [@colonna2026]

• Disease stage: DAM may be protective early (clearing pathological ) but become dysfunctional and neurotoxic with chronic activation
• Brain region: DAM responses vary by brain region, with different functional consequences in /hippocampus|[hippocampus](/brain-regions/hippocampus) vs. [cortex](/brain-regions/cortex)
• Genetic background: APOE/Alzheimer's) disease]:
• AL002 (Alector/AbbVie): Anti-TREM2 antibody in Phase 2 trials for early AD
• Mechanism: Enhances TREM2 signaling to promote DAM activation, phagocytosis, and amyloid clearance
• Challenges: Optimal TREM2 expression level is critical — too much or too little may be harmful (Claes et al., 2026)

Modulating the TREM2-APOE Axis

• Targeting apoe

Phenotype Switching

• Promoting beneficial DAM functions while suppressing neurotoxic properties
• Selectively enhancing phagocytic capacity without inflammatory activation
• Temporal control of DAM activation (promote early, suppress late)

Biomarker Applications

• Soluble TREM2 (sTREM2) in CSF as a biomarker of microglial activation
• PET tracers for activated microglia (TSPO ligands) to image DAM in vivo
• Blood-based reflecting DAM state for clinical monitoring

Key Transcription Factors

Several transcription factors regulate the DAM program:

• Bhlhe40: Commonly induced in reactive microglia through TREM2-apoe signaling
• Tfec: Lysosomal gene regulator activated in DAM
• Atf3: Stress-response transcription factor upregulated in DAM
• SPI1 (PU.1): Master regulator of myeloid cell identity; AD risk locus that may influence DAM activation threshold
• MEF2C: Homeostatic microglial transcription factor downregulated in DAM

Recent Research Updates (2024-2026)

This section highlights recent publications relevant to this mechanism.

• [Neuromodulatory role and therapeutic potential of N6-methyladenosine RNA methylation in neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/) (2026)
• [P2X7 receptors as targets for neuroprotection](https://pubmed.ncbi.nlm.nih.gov/) (2026)
• [Mitochondrial damage-associated molecular patterns: Neuroimmunomodulators in central nervous system pathophysiology](https://pubmed.ncbi.nlm.nih.gov/) (2026)
• [Inflammation-induced Neuronal Damage in CNS Tuberculosis: Molecular Mechanism and Therapeutic Targets](https://pubmed.ncbi.nlm.nih.gov/) (2026)
• [Persistent microglial activation following neonatal CMV infection mediates neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/) (2016)

Confidence Assessment

Recent studies further refine neuroinflammation-microglia (Nature) identifies protective state modules within microglia" title="Goate et al., Lymphoid gene expression supports neuroprotective microglia function (2025)">[@goate2025]

• 2025: PICALM Alzheimer's risk allele causes aberrant lipid droplets in microglia (Nature) links AD risk variation to dysfunctional lipid buffering and altered phagocytic resilience in microglial populations.[@mullard2025]
• 2026: The gain-of-function TREM2-T96K mutation increases risk for Alzheimer's Disease by impairing microglial function (neurons) resolves a receptor-signaling paradox where stronger in vitro signaling maps to weaker in vivo microglial homeostasis.[@colonna2026]

Recent Research Updates (2024-2026)

This section highlights recent publications relevant to this mechanism.

• Neuromodulatory role and therapeutic potential of N 6 -methyladenosine RNA methylation in neurodegenerative . (2026 Jun 1) - Neural regeneration research
• P2X7 receptors as targets for neuroprotection. (2026 May 15) - Neuropharmacology
• Mitochondrial damage-associated molecular patterns: Neuroimmunomodulators in central nervous system pathophysiology. (2026 Apr 1) - Neural regeneration research
• Inflammation-induced Neuronal Damage in CNS Tuberculosis: Molecular Mechanism and Therapeutic Targets. (2026 Mar 15) - Brain research
• Persistent microglial activation following neonatal CMV infection mediates neurodegeneration. (2026 Mar 13) - Science advances

Confidence Assessment

🔴 Low Confidence

| Dimension | Score |
|